Pharmaceutical compositions comprising lonafarnib and ritonavir
Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
1. A method of treating a hepatitis delta virus (HDV) infection in a human patient with an HDV infection, comprising:
orally administering to the human patient a therapeutically effective amount of an amorphous co-precipitate comprising:
lonafarnib or a pharmaceutically acceptable salt thereof; and
ritonavir or a pharmaceutically acceptable salt thereof;
wherein the amorphous co-precipitate is substantially free of crystalline forms, and
wherein the amorphous co-precipitate is administered at a daily dose of lonafarnib of 50 mg to 200 mg once daily or twice daily.
2. The method of claim 1 , wherein the lonafarnib or the pharmaceutically acceptable salt thereof and the ritonavir or the pharmaceutically acceptable salt thereof are present in the amorphous co-precipitate in a ratio of 0.5:1 to 2:1 (w/w).
3. The method of claim 1 , wherein the amorphous co-precipitate is administered once daily.
4. The method of claim 1 , wherein the human patient is treated with the amorphous co-precipitate for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days.
5. The method of claim 1 , wherein the human patient is treated with the amorphous co-precipitate for rest of life of the human patient or until the administering is no longer effective in maintaining HDV at a sufficiently low level to provide meaningful therapeutic benefit.
6. The method of claim 1 , further comprising administering to the human patient a gastrointestinal modifying agent.
7. The method of claim 1 , wherein the amorphous co-precipitate is formulated as a tablet, caplet, gelcap, or a capsule.
8. The method of claim 1 , wherein the HDV infection is a chronic HDV infection.
9. A method of treating a hepatitis delta virus (HDV) infection in a human patient with an HDV infection, comprising:
orally administering to the human patient a therapeutically effective amount of an amorphous co-precipitate comprising:
lonafarnib or a pharmaceutically acceptable salt thereof; and
ritonavir or a pharmaceutically acceptable salt thereof;
wherein the amorphous co-precipitate is substantially free of crystalline forms, and
wherein the amorphous co-precipitate is administered once daily or twice daily.
10. The method of claim 9 , wherein the amorphous co-precipitate administered to the human patient comprises the lonafarnib or the pharmaceutically acceptable salt thereof in an amount from about 20 mg to about 100 mg.
11. The method of claim 9 , wherein the amorphous co-precipitate is administered once daily.
12. The method of claim 9 , wherein the human patient is treated with the amorphous co-precipitate for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days.
13. The method of claim 9 , wherein the human patient is treated with the amorphous co-precipitate for rest of life of the human patient or until the administering is no longer effective in maintaining HDV at a sufficiently low level to provide meaningful therapeutic benefit.
14. The method of claim 9 , further comprising administering to the human patient a gastrointestinal modifying agent.
15. The method of claim 9 , wherein the amorphous precipitate is formulated as a tablet, a caplet, a gelcap, or a capsule.
16. The method of claim 9 , wherein the HDV infection is a chronic HDV infection.
17. A composition comprising an amorphous co-precipitate comprising: lonafarnib or a pharmaceutically acceptable salt thereof; ritonavir or a pharmaceutically acceptable salt thereof; and a co-polymer;
wherein the amorphous co-precipitate is substantially free of crystalline forms,
wherein the composition is formulated for oral administration, and
wherein the composition comprises the lonafarnib or the pharmaceutically acceptable salt thereof in an amount from about 20 mg to about 100 mg.
18. The composition of claim 17 , wherein the composition is formulated as a tablet, caplet, gelcap, or a capsule.
19. A unit dosage form comprising a composition of claim 17 .
20. A unit dosage form comprising a composition of claim 17 , wherein the unit dosage form is formulated as a tablet, a caplet, a gelcap, or a capsule.